STRO

What the company does

Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.

Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

• 2026-05-14share offering or dilution eventrecentOpen filing ↗
  “…primarily from upfront, milestone and other payments under our collaboration agreements with BMS, Merck, Astellas, Vaxcyte, Ipsen,…”
  +1 more passage from the same document

  • “…capital to support and expand such activities and providing general and administrative support for these operations. We have…”
• 2026-05-14listing compliance noticerecentOpen filing ↗
  “…among other things, that the minimum bid price of a listed company’s stock be at or above $1.00. On June 20, 2025, we received…”
  +1 more passage from the same document

  • “…dramatic and adverse impact on the market price of our common stock. If we fail to maintain compliance with Nasdaq’s minimum listing…”
• 2026-05-14reverse splitrecentOpen filing ↗
  “…Company to maintain its operations for a period of at least 12 months following the filing date of these interim condensed…”
  +1 more passage from the same document

  • “…operations for a period of at least 12 months following the filing date of these interim condensed financial statements. 9 Reverse…”
• 2026-04-01capital return (buybacks/dividends)recentOpen filing ↗
  “…the method used to determine such rate or rates; • the date or dates from which interest, if any, will be payable and any…”
  +1 more passage from the same document

  • “…the offering price, if any, and the exercise price are payable; • if applicable, a discussion of material U.S. federal income tax…”
• 2026-03-23capital return (buybacks/dividends)recentOpen filing ↗
  “…the method used to determine such rate or rates; • the date or dates from which interest, if any, will be payable and any…”
  +1 more passage from the same document

  • “…the offering price, if any, and the exercise price are payable; • if applicable, a discussion of material U.S. federal income tax…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

Reverse splits in 5 years

1 reverse split in 5 years (1:10 on Dec 3, 2025) · 1:10 cumulative

The other times: of 818 securities that did their first reverse split in 5 years, a year later the median was worth 0.53× the price on the day of the split; 382 lost more than half and 209 rose (809 with a price a year later).

Our own series, not the whole market: based on the splits we have on record (provider and SEC); an unrecorded one does not count. Historical distribution, not a prediction.